Authors
Latest:
Andrew Y. Sun, MD, on the role for APPs in men’s health"I joke that on face value, the APPs work for me, but I feel like I'm really working for them, because they basically do everything except for the surgery," says Andrew Y. Sun, MD.
Latest:
Investigational HIF-2α inhibitor shows activity, safety in advanced clear cell RCCThis monotherapy was safe for all doses and dosing schedules observed in the study and daily doses showed initial antitumor activity.
Latest:
Update on advanced imaging in prostate cancerAdvances allow for more accurate detection of metastatic disease.
Latest:
Martin Sanda, MD, considers potential future advancements in urologyAccording to Sanda, future advancements may involve gene and RNA sequencing, the use of AI in imaging, and multidisciplinary collaboration.
Latest:
The emotional toll of surgical complications on urologic surgeons"It is important as a field that we recognize the potential emotional impact of surgical adverse events," writes Amy N. Luckenbaugh, MD.
Latest:
Lymph nodes in bladder cancer: Past, present, and future"Based on the LEA and S1011 trials, it has become clear that patients do not benefit from an extended LND, and a standard bilateral pelvic LND is the standard of care," write Amir Soltani-Tehrani, MD, and Kamal S. Pohar, MD.
Latest:
Ongoing Studies Investigating Rectal Spacer Benefits in Patients With Prostate Cancer Undergoing Radiation TherapyDr Daniel Allan Hamstra highlights ongoing and planned trials investigating rectal spacers in patients with prostate cancer undergoing radiation therapy that he hopes will provide more data on toxicity reduction and preservation of sexual function.
Latest:
Trends in urology: Arpeet Shah, MD, on challenges and opportunities in 2025Arpeet Shah, MD, highlights the shift toward precision medicine, ongoing work force challenges, the integration of AI, and more.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Brendan Browne, MD, on patient selection for HoLEP for BPH“The patients I find that have the most pronounced benefit are the patients with the very large prostates, or the patients who are catheter dependent with concern for neurogenic or myogenic bladder failure,” says Brendan M. Browne, MD.
Latest:
How to implement an ERAS pathway in your urology practiceProgram encompasses patient counseling, anesthetic planning, and early mobilization.
Latest:
AACU 2024 Advocacy Summit & Annual MeetingThis year, the AACU 2024 Advocacy Summit & Annual Meeting will focus on the intersection of health policy and clinical practice, as well as the impact of current state and national legislative trends on urology.
Latest:
Why a personalized approach is key to prolapse and OAB management“What's really cool about overactive bladder is that, it's not like high blood pressure. They do not have to leave this office with a pill in hand," says Anna Myers, CNP.
Latest:
Current and Emerging Treatment Landscape of mHSPCJack Andrews MD; Eugene Cone, MD; and Arash Rezazadeh, MD, discuss how metastatic hormone-sensitive prostate cancer presents clinically, explore current treatment standards including combination therapies, evaluate emerging data from the ARANOTE trial on darolutamide efficacy, consider quality of life factors in treatment selection, and examine how novel therapeutic approaches may reshape future care pathways.
Latest:
Expert Forum: Fertility after exogenous testosterone replacementTreatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.
Latest:
Distinguishing between malignant and benign renal masses"Augmented biopsy-based and noninvasive options are available to reduce benign resection rates of renal tumors with the consideration of PEER and 99mTc-sestamibi SPECT/CT," writes Hiten D. Patel, MD, MPH.
Latest:
What determines the optimal urinary diversion?"Ultimately, there is no 'right choice' when it comes to urinary diversion," writes Anne K. Schuckman, MD.
Latest:
Optimization of Genetic Testing for mCRPCJason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.
Latest:
Diagnostic stewardship for urinary tract infection: A snapshot of the expert guidanceUrinary tract infections (UTIs) are among the most common human infections. But the urine culture, the cornerstone for laboratory diagnosis of UTI, is imperfect.
Latest:
How to implement an ERAS pathway in your urology practiceProgram encompasses patient counseling, anesthetic planning, and early mobilization.
Latest:
The American Board of Urology: Considerations for the urologist in career transitions"The ABU continues to reevaluate all policies related to diplomates. As medical practice continues to evolve in United States, and these changes affect the practitioners of medicine, likely further changes will be necessary in board certification procedures," writes Roger Dmochowski, MD, MA (Conflict Management and Resolution), MMHC, FACS.
Latest:
UCI receives renewal as Orange County’s only federally designated comprehensive cancer centerThe National Cancer Institute has again recognized the UCI Chao Family Comprehensive Cancer Center as one of the nation’s top cancer centers, renewing its “comprehensive” designation
Latest:
Rana McKay, MD, on the role of radium-223 in the modern era"Radium-223 continues to have a very significant role for patients with advanced castration-resistant prostate cancer," says Rana R. McKay, MD, FASCO.
Latest:
Looking Ahead: Image-Guided Diagnostic ToolsKyrollis Attalla, MD, remarks on emerging imaging technologies for patients with prostate cancer and the growing pool of candidates for focal therapy.
Latest:
Legislative efforts to eliminate barriers to prostate cancer screening ramp up"Our success depends on your assertive action and membership in organizations serving our specialty—the AACU in particular—as well as your state medical association," writes William C. Reha, MD, MBA.
Latest:
Use and Sequencing of Novel Treatments in NMIBCExperts discuss where they are using FDA-approved treatments for bacille Calmette-Guérin (BCG)–unresponsive patients in their practice, how they choose between these treatments, and how these advances have impacted the timing of radical cystectomy for patients.
Latest:
2024 Urology Times pipeline reportCatch up on all the notable drug and device approvals in urology over the past year.
Latest:
MIPS success: What specialists need to know"Specialty providers can take three steps now to succeed with MIPS while prioritizing caring for their patients," writes Wayne Singer.
